Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte ™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval PRINCETON, N.J., Feb. 14, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage... (Source: - Clinical Trials)
Source: - Clinical Trials - February 14, 2023 Category: Pharmaceuticals Source Type: clinical trials

Photopheresis in Early-stage Mycosis Fungoides
Conditions:   Cutaneous T Cell Lymphoma;   Mycosis Fungoides Interventions:   Drug: UVADEX® (methoxsalen) Sterile Solution in conjunction with the UVAR® THERAKOS® CELLEX Photopheresis;   Device: THERAKOS® CELLEX photopheresis system Sponsor:   Columbia University Recruiting (Source:
Source: - January 11, 2023 Category: Research Source Type: clinical trials